| Income Statement | 2026-06-30 | 2026-03-31 | 2025-12-31 | |
|---|---|---|---|---|
| Research and development | 4,262 | 4,552 | 3,329* | |
| General and administrative | 5,117 | 4,729 | 3,853* | |
| Total operating expenses | 9,379 | 9,281 | 7,181 | |
| Loss from operations | -9,379 | -9,281 | -7,181* | |
| Change in fair value of warrant derivative | 0 | 0 | -38* | |
| Fair value loss from standby equity purchase agreement (sepa arrangement) | 0 | - | -97* | |
| Foreign exchange gain (loss) | 1 | -6 | -26* | |
| Interest income | 37 | 44 | 97* | |
| Total other income, net | 38 | 38 | 11* | |
| Loss before income taxes | -9,341 | - | -7,170* | |
| Income tax expense | 101 | - | 20* | |
| Net loss | -9,442 | -9,243 | -7,190* | |
| Translation adjustments | 0 | 0 | -34* | |
| Comprehensive loss | -9,442 | -9,243 | -7,224 | |
| Basic EPS | -0.08 | -0.08 | -0.075 | |
| Diluted EPS | -0.08 | -0.08 | -0.075 | |
| Basic Average Shares | 119,739,942 | 112,292,579 | 95,857,147 | |
| Diluted Average Shares | 119,739,942 | 112,292,579 | 95,857,147 | |
ONCOLYTICS BIOTECH INC (ONCY)
ONCOLYTICS BIOTECH INC (ONCY)